Most of these data were obtained with the BTK inhibitor ibrutinib and the PI3Kδ inhibitor idelalisib, which induce clinical responses in the vast majority of patients with CLL, MCL, and WM and in approximately half of the patients with FL and MZL (Table 1). This evidence concerns the gene BTK and mantle cell lymphoma.